Boehringer Ingelheim GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Boehringer Ingelheim GmbH
Moderna has unveiled plans to develop a new booster vaccine, tweaked to meet the threat posed by the South African strain.
Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic.
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
- Other Names / Subsidiaries
- AMAL Therapeutics SA
- ICD Therapeutics
- SSP Co., Ltd.
- Vira Therapeutics GmbH (Vira T)